NICE recommends Merck's Keytruda for treating advanced skin cancer

7 September 2015

The UK’s National Institute for Health and Care Excellence has recommended Keytruda (pembrolizumab) from Merck & Co (NYSE: MRK) for treating advanced skin cancer.

Keytruda will be made available on the National Health Service as a treatment for some patients with advanced melanoma, which is either unresectable or metastatic. It has a marketing authorization in the UK as monotherapy ‘for the treatment of advanced unresectable or metastatic melanoma in adults.’

The NICE has recommended Keytruda for after the disease has progressed with ipilumab and, for BRAF V600 mutation-positive disease, a BRAF or MEK inhibitor and when the company provides pembrolizumab with the discount agreed in the patient access scheme.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK